IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed May 10, 2022 · 10-Q · 40 days after period end · 0000950170-22-009040
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Net Income | -$21.64M | -$23.09M | -$17.18M | -$5.68M |
| EPS Diluted | -$0.72 | -$0.78 | -$0.61 | -$1.61 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Mar 31, 2022 · filed May 10, 2022 · 40 d after period end
